The global market for emerging insulin drug delivery devices is expected to grow from $55.8 billion in 2023 and projected to reach $88.9 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.8% from 2023 through 2028.
The global market for insulin syringes and vials is expected to grow from $24.3 billion in 2023 and projected to reach $37.0 billion by the end of 2028, at a CAGR of 8.7% from 2023 through 2028.
The global market for smart insulin pens is expected to grow from $4.2 billion in 2023 and projected to reach $7.7 billion by the end of 2028, at a CAGR of 12.6% from 2023 through 2028.
Report Scope:
This report discusses the implications of the growing diabetes epidemic on the global and regional markets for emerging insulin drug and delivery technologies. It discusses companies in the relevant pharmaceutical and medical industries and provides profiles of the leading players as well as an update on M&A activity. The report's patent analysis focuses on developments in Japan, Europe and the U.S. Five-year global sales forecasts are provided for the major categories of insulin drug and delivery technologies and devices categories.
This report segments the global market into four regions -
- North America.
- Europe.
- Asia-Pacific.
- Rest of the World (RoW).
Report Includes:
- 57 data tables and 83 additional tables
- An overview and industry analysis of the global markets for emerging insulin drug and delivery technologies, with an emphasis on plastic insulin syringes and vials
- Analyses of the global market trends, with historical market revenue data (sales figures) for 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
- Estimate of the actual market size and revenue growth forecast, and a corresponding market share analysis by product type, application and region
- A look at the emerging technologies that have potential in the diabetes market, with improved glucose control, along with improved delivery methods
- Examination of the current state of the insulin drug and delivery industry structure, focusing on technological updates and issues surrounding insulin pens and insulin syringes, ongoing research activities, and regulatory and pricing scenarios
- Discussion of market dynamics, clinical trial applications, regulations, and penetration of technologies in the pharmaceutical and biotechnology markets
- Discussion of the ESG developments and how they impact corporate performance, ratings and matrices and consumer attitude, as well as the ESG practices of leading pharma and biotech companies
- Review of the key patent grants/publications for insulin as a drug, along with its delivery methods
- Analysis of the competitive landscape based on recent developments and segmental revenues of leading companies
- Profiles of the leading market players